Shanghai Henlius Biotech   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Shanghai China (2009)
Status: No NME R&D (2009)

Organization Overview

First Clinical Trial
2014
NCT03218072
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Shanghai Henlius Biotech

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 3)

Arthritis, Rheumatoid (Phase 3)

Breast Neoplasms (Phase 3)

Carcinoma (Phase 3)

Carcinoma, Hepatocellular (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Squamous Cell (Phase 3)

Colorectal Neoplasms (Phase 3)

Disease Progression (Phase 2)

Esophageal Squamous Cell Carcinoma (Phase 3)

Head and Neck Neoplasms (Phase 2)

Immune System Diseases (Phase 1)

Lung Neoplasms (Phase 3)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 3)

Lymphoma, Follicular (Phase 3)

Neoplasms (Phase 2)

Psoriasis (Phase 3)

Small Cell Lung Carcinoma (Phase 3)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Stomach Neoplasms (Phase 3)

Triple Negative Breast Neoplasms (Phase 3)

Uterine Cervical Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 68
  • # of Trial APIs: 43